Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$887.49 USD

887.49
330,178

+3.01 (0.34%)

Updated Oct 2, 2024 10:32 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Eli Lilly (LLY) Tops Q4 Earnings & Sales, Ups 2018 View

by Zacks Equity Research

Eli Lilly (LLY) beat estimates on both counts in its fourth quarter earnings results.

    Drug/Biotech Stocks Q4 Earnings Due on Jan 31: LLY & VRTX

    by Zacks Equity Research

    Two pharma/biotech giants are scheduled to report earnings on Jan 31. Let's take a look at how the companies are placed ahead of the upcoming releases.

      Lilly (LLY) to Report Q4 Earnings: What's in the Cards?

      by Zacks Equity Research

      Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

        Arpita Dutt headshot

        AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call

        by Arpita Dutt

        With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.

          Merck Reports Positive Phase III Liver Cancer Data on Keytruda

          by Zacks Equity Research

          Merck (MRK), announces first time results from the phase II study evaluating the use Keytruda in patients with advanced hepatocellular carcinoma (HCC), previously treated with sorafenib.

            Merck Strong on Confirmatory Phase III Lung Cancer Study

            by Zacks Equity Research

            Merck's (MRK) Keytruda in combination with Eli Lilly's Alimta and carboplatin meet dual primary endpoints in a confirmatory phase III study for the first-line treatment of lung cancer.

              Nektar Boasts Strong Pipeline, Competition Remains a Woe

              by Zacks Equity Research

              Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.

                Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod

                by Zacks Equity Research

                Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.

                  Merck's Keytruda on a Roll: Can it Retain the Spark in 2018?

                  by Zacks Equity Research

                  Merck's (MRK) Keytruda rapidly grows as its key top-line driver. The Keytruda development program shows significant advancement in 2017.

                    Big Pharma CEOs Speak About Impact of Tax Reform on M&A

                    by Zacks Equity Research

                    This week, senior executives of some large drug companies discussed the impact of tax reform on mergers and acquisition and their plans to use the excess cash at the JP Morgan HealthCare conference.

                      Arpita Dutt headshot

                      FDA Approvals Surge in 2017: Here's a Look at the Numbers

                      by Arpita Dutt

                      There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers and what lies ahead.

                        Pfizer to Stall R&D for Alzheimer's/Parkinson's, Cut Jobs

                        by Zacks Equity Research

                        Pfizer (PFE) will reportedly end R&D efforts in Alzheimer's and Parkinson's disease areas, which will result in about 300 job cuts.

                          Arpita Dutt headshot

                          Alzheimer's takes Another Hit as Pfizer Ends Research in this Area

                          by Arpita Dutt

                          With pharma major, Pfizer (PFE), announcing its intention to drop plans to develop treatments for Alzheimer's and certain other disease areas, here is a look at what is going on in this corner of the market.

                            Merck's Keytruda Gets Approved for Bladder Cancer in Japan

                            by Zacks Equity Research

                            Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.

                              ImmunoGen (IMGN) Soars Above 200% This Year: Here's Why

                              by Zacks Equity Research

                              ImmunoGen's (IMGN) shares shoot up in the year on rapid pipeline progress, positive study data and strategic collaborations.

                                The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom

                                by Zacks Equity Research

                                The Zacks Analyst Blog Highlights: Bio-Rad Laboratories, Mazor Robotics, Tactile Systems, Eli Lilly and DexCom

                                  Biogen's Alzheimer's Drug Misses Goal in Interim Analysis

                                  by Zacks Equity Research

                                  Biogen (BIIB) Alzheimer's candidate, BAN2401, failed to meet the criteria for success based on a 12 months interim analysis as the primary endpoint in a mid-stage trial.

                                    AbbVie's RA Candidate Meets Endpoints in 3rd Phase III Study

                                    by Zacks Equity Research

                                    AbbVie's (ABBV) RA candidate, upadacitinib, achieves statistically significant improvement in patients in phase III monotherapy study comparing it to methotrexate.

                                      Arpita Dutt headshot

                                      3 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2018

                                      by Arpita Dutt

                                      Immuno-oncology was a key focus area in 2017 - will it remain so in 2018 as companies like Juno (JUNO) progress with their pipelines?

                                        Novartis (NVS) Oncology Head Strigini to Step Down by Dec. 31

                                        by Zacks Equity Research

                                        Novartis (NVS) is at a transitional stage as the CEO of its oncology segment will step down by the end of year. The company's CEO is also going to step next year.

                                          Radius Health to Get Third Day-180 List of Outstanding Issues

                                          by Zacks Equity Research

                                          Radius Health (RDUS) will get a third Day-180 List of Outstanding Issues from the CHMP for its marketing authorisation application of abaloparatide-SC leading to a further delay in tentative approval.

                                            Spectrum Pharma Dismisses CEO, Makes Leadership Changes

                                            by Zacks Equity Research

                                            Spectrum Pharma (SPPI) terminates Rajesh Shrotriya and appoints its present COO, Joseph Turgeon, as the new CEO.

                                              Merck's Keytruda Misses Primary End Point for Gastric Cancer

                                              by Zacks Equity Research

                                              Merck's (MRK) anti-PD-1 therapy Keytruda misses the primary endpoint in a phase III study, which analyzed it as a second-line treatment for patients with advanced gastric adenocarcinoma.

                                                Lilly Issues Guidance for 2018, New Drugs to Drive Top Line

                                                by Zacks Equity Research

                                                Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.

                                                  Intersect ENT (XENT) SINUVA Implant Receives FDA Approval

                                                  by Zacks Equity Research

                                                  Intersect ENT's (XENT) consistent focus on the chronic sinusitis market is likely to lend the company a competitive edge in the niche space.